Related Experiment Videos
[New therapies in type 2 diabetes]
N Neyrolles1, J F Blicklé, J M Brogard
1Service de Médecine Interne B, Hôpital Civil, Strasbourg.
Annales D'Endocrinologie
|October 28, 1998
Summary
New non-insulin-dependent diabetes mellitus (NIDDM) therapies offer improved management. These include drugs stimulating insulin secretion, reducing insulin resistance, or mimicking insulin, plus alpha-glucosidase inhibitors for post-meal sugar control.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Non-insulin-dependent diabetes mellitus (NIDDM) management is evolving with novel therapeutic agents.
- Understanding drug targets is crucial for classifying new NIDDM treatments.
Purpose of the Study:
- To review and classify emerging therapeutic developments for NIDDM.
- To highlight the role of alpha-glucosidase inhibitors in managing postprandial hyperglycemia.
Main Methods:
- Literature review of NIDDM therapeutic advancements.
- Classification of drugs based on their mechanism of action: insulin secretion stimulation, insulin resistance reduction, insulin mimicry, and carbohydrate digestion inhibition.
Main Results:
- New NIDDM drugs target insulin secretion (e.g., glimepiride, repaglinide, glucagon-like peptide 1), insulin resistance (thiazolidinediones), or act as insulin mimetics (vanadium).
- Alpha-glucosidase inhibitors delay carbohydrate digestion, effectively reducing postprandial hyperglycemia.
Conclusions:
- Novel NIDDM medications offer safer profiles and simplified dosing regimens.
- These agents provide alternatives to traditional oral antidiabetics, enabling combination therapies for comprehensive NIDDM management.